Clinical Trial

Diabetes RElated to Acute Pancreatitis and Its Mechanisms

Study acronym: DREAM
Recruiting
View on ClinicalTrials.gov →
Summary
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-01-14; most recent amendment 2025-11-17.
Trial Details
NCT Number NCT05197920
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Benaroya Research Institute, Cedars-Sinai Medical Center, University of Southern California, Indiana University, Johns Hopkins University, Ohio State University, Stanford University, University of Florida, AdventHealth, University of Illinois at Chicago, Northwestern University, University of Minnesota, University of Pittsburgh
Conditions Acute Pancreatitis
Enrollment 800 participants
Start Date 2022-01-14
Primary Completion 2030-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-18